In this episode of The Healthy Enterprise, host Brian Newsom discusses his journey in the biotechnology field, focusing on his role as CEO of Carrigent, a company specializing in cell and gene therapy. He elaborates on the innovative vector technology being developed for targeted payload delivery, the challenges of fundraising in the current market, and the integration of AI to enhance operational efficiency. Brian also shares insights into the importance of strategic partnerships and the ultimate goal of bringing therapeutic solutions to patients. In this conversation, the speaker discusses the importance of building long-term relationships in healthcare, particularly in the context of gene therapy. They share insights on leadership styles, emphasizing trust and autonomy within teams. The challenges of being a founder are explored, along with the need for inspiration and motivation in tough times. The discussion also touches on the intersection of science fiction and current scientific advancements, future trends in healthcare, and advice for aspiring professionals in the field.

Chapters

00:00 Introduction to Cell and Gene Therapy Innovations

03:04 Exploring Vector Technology and Its Applications

05:59 Brian Newsom's Journey: From Science to Business

09:08 Leveraging AI and Technology in Biotech

11:59 Navigating Fundraising Challenges in Biotech

14:49 Strategic Partnerships and Market Positioning

22:12 Building Long-Term Relationships in Healthcare

23:27 Leadership Style and Team Dynamics

26:00 The Challenges of Foundership

28:32 Finding Inspiration and Motivation

31:12 The Intersection of Science Fiction and Reality

33:03 Future Trends in Healthcare

35:34 Advice for Aspiring Professionals

37:17 Navigating Tough Times in the Industry

Guest Information:

• Guest's Name: Brian Newsom
• Guest's Title/Position: Chief Executive Officer
• Guest's Linkedin: https://www.linkedin.com/in/brian-newsom/
• Company / Affiliation: Carrigent https://carrigent.com/
• Guest's Bio: Brian Newsom is the founding CEO of the vector technology company, Carrigent, as well as the VP of Business Development for the cell therapy CDMO, Theragent. Prior to this, Brian spent six years at KBI Biopharma and almost a decade at Thermo Fisher Scientific (and legacy companies) in business development. Brian’s technical background includes posts as Head of R&D at Opexa Therapeutics and five years at Baylor College of Medicine, Center for Cell and Gene Therapy. Brian began his career in cell therapy at Aastrom Biosciences, one of the industries pioneering companies, in 1992. Brian received his degree in Microbiology from Texas Tech University and an MBA from Texas A&M University.

Takeaways:

• Brian Newsom is the CEO of Carrigent, focusing on cell and gene therapy.
• Carrigent is developing a next-generation payload delivery system.
• The company is exploring applications in oncology, metabolic, and neurodegenerative diseases.
• Brian transitioned from a scientific role to business development to have a broader impact.
• AI is being leveraged to create efficiencies in biotech operations.
• Fundraising in biotech is currently challenging due to market conditions.
• Strategic partnerships are essential for asset development and exposure.
• The ultimate goal is to partner with pharma and biotech for therapeutic development.
• Brian's diverse background provides a unique perspective in the industry.
• The end users of their technology will be pharma and biotech companies. Building long-term relationships is crucial in healthcare.
• Leadership involves trusting your team to do their jobs.
• Founders often struggle to let go of their vision.
• Inspiration can come from various sources, including literature.
• Science fiction often predicts future scientific advancements.
• Early diagnostics are essential for effective treatment.
• The healthcare industry is evolving with new therapies.
• Resilience is key in navigating industry challenges.
• Patient care should be the primary motivation for professionals.
• The future of healthcare will focus on curing chronic diseases.